Legal Representation
Attorney
Monte L. Falcoff/Jessica S. Sachs
USPTO Deadlines
Next Deadline
847 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-11-02)
Due Date
November 02, 2027
Grace Period Ends
May 02, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
48 events| Date | Code | Type | Description |
|---|---|---|---|
| May 4, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| May 15, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Apr 21, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Apr 21, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Feb 2, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Nov 2, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 23, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 17, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 17, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 14, 2021 | GPNX | P | NOTIFICATION PROCESSED BY IB |
| Jul 28, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Jul 28, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 28, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Jul 14, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 13, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 13, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 9, 2021 | ALIE | A | ASSIGNED TO LIE |
| May 25, 2021 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| May 10, 2021 | CHLD | M | CHANGE OF OWNER RECEIVED FROM IB |
| Apr 9, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Apr 6, 2021 | CORN | I | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Apr 3, 2021 | CRCV | M | CORRECTION TRANSACTION RECEIVED FROM IB |
| Mar 5, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Jan 26, 2021 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Jan 26, 2021 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Jan 26, 2021 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Jan 19, 2021 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Jan 19, 2021 | EXPI | T | EX PARTE APPEAL-INSTITUTED |
| Jan 19, 2021 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Jan 19, 2021 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB |
| Oct 26, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Oct 26, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Oct 26, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 20, 2020 | CNFR | R | FINAL REFUSAL WRITTEN |
| Jul 20, 2020 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Jul 20, 2020 | GNFR | O | FINAL REFUSAL E-MAILED |
| Jul 14, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 14, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 14, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 15, 2020 | RFNT | P | REFUSAL PROCESSED BY IB |
| Apr 28, 2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Apr 28, 2020 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Apr 11, 2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Apr 10, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Apr 1, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 17, 2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Mar 13, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 12, 2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 042
Study in the nature of conducting scientific feasibility studies and design of production factories and buildings; inspection of production factories and buildings for quality control and consultancy purposes; engineering; preparation of technical studies; quality control of production units in the pharmaceutical and biopharmaceutical field with a view to certification; research and development of new products for third parties; technological services regarding manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
Additional Information
Pseudo Mark
OXYGEN
Classification
International Classes
042